NDAORALCAPSULEPriority Review
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRUSELTIQ (infigratinib phosphate) is an oral small-molecule fibroblast growth factor receptor (FGFR) inhibitor approved by the FDA in May 2021. It is indicated for cholangiocarcinoma patients with FGFR2 gene fusions or rearrangements. The drug works by selectively inhibiting FGFR signaling to block tumor growth in this genetically defined population.
$0.351MPart D
Peak8.1 years to LOEEarly commercialization phase with limited Part D penetration; significant opportunity to expand awareness and patient access in a niche precision oncology segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRUSELTIQ offers deep expertise in precision oncology, companion diagnostics, and niche market development—critical differentiators in modern pharma. The small patient population and unmet need create meaningful career impact in driving diagnosis and access for a rare genetic subset within a lethal disease.
Oncology Brand ManagerMedical Science Liaison
Worked on TRUSELTIQ at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.